Evidence map›Paper›PMID 37277117›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2023

Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease.

Jesús Delgado-Calle, G David Roodman

Abstract readEditorialComment
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jesús Delgado-CallePhysiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0002-2083-2774
G David RoodmanDepartment of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Funding

Understanding the Negative Prognostic Impact of Intraosseous Focal Lesions in Multiple MyelomaP20GM125503 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI CHARLES A O'BRIEN · 2018 to 2026
$23.0M
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple MyelomaR01CA209882 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI Teresita M. Bellido, Jesus Delgado-Calle · 2017 to 2026
$3.8M
Bone-Targeted Therapies to Improve Bone Health and Prevent Relapse in Multiple MyelomaR37CA251763 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI DELGADO-CALLE, JESUS · 2020 to 2025
$2.6M
Osteoclast-Osteocyte Interaction's in Paget's DiseaseR01AR080116 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI NORIYOSHI KURIHARA · 2022 to 2026
$2.4M
Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone DiseaseR01CA241677 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI CHIRGWIN, JOHN M · 2020 to 2024
$1.6M
Role of Microenvironmental-Derived AXII in Myeloma Bone DiseaseI01CX000623 · VA · VETERANS HEALTH ADMINISTRATION · PI Attaya Suvannasankha · 2013 to 2026
–
CSRD VA I01 CX000623NCI NIH HHS R01 CA209882NCI NIH HHS R01 CA241677NCI NIH HHS R37 CA251763NIAMS NIH HHS R01 AR080116NIGMS NIH HHS P20 GM125503
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone DiseasesMultiple MyelomaCell Line, TumorHumansWnt ProteinsWnt Signaling PathwayWnt Proteins

Identifiers

PMID37277117
PMCPMC10330486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.